Shukra Pharmaceuticals Intrinsic Value
SHUKRAPHAR Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹19.80 | ₹15.84 - ₹23.76 | -58.1% | EPS: ₹0.90, Sector P/E: 22x |
| Book Value Method | asset | ₹28.64 | ₹25.78 - ₹31.50 | -39.5% | Book Value/Share: ₹14.32, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹18.18 | ₹16.36 - ₹20.00 | -61.6% | Revenue/Share: ₹9.09, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹38.64 | ₹34.78 - ₹42.50 | -18.3% | EBITDA: ₹17.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹24.70 | ₹19.76 - ₹29.64 | -47.8% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹14.19 | ₹12.77 - ₹15.61 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹14.51 | ₹13.06 - ₹15.96 | -69.3% | Revenue Growth: 15.0%, Adj P/E: 16.1x |
| ROE Based Valuation | profitability | ₹38.18 | ₹34.36 - ₹42.00 | -19.3% | ROE: 19.0%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹17.03 | ₹15.33 - ₹18.73 | -64.0% | EPS: ₹0.90, BVPS: ₹14.32 |
Want to compare with current market value? Check SHUKRAPHAR share price latest .
Valuation Comparison Chart
SHUKRAPHAR Intrinsic Value Analysis
What is the intrinsic value of SHUKRAPHAR?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Shukra Pharmaceuticals (SHUKRAPHAR) is ₹19.80 (median value). With the current market price of ₹47.30, this represents a -58.1% variance from our estimated fair value.
The valuation range spans from ₹14.19 to ₹38.64, indicating ₹14.19 - ₹38.64.
Is SHUKRAPHAR undervalued or overvalued?
Based on our multi-method analysis, Shukra Pharmaceuticals (SHUKRAPHAR) appears to be trading above calculated value by approximately 58.1%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 9.29 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.38 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 19.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 27.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.46x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Shukra Pharmaceuticals
Additional stock information and data for SHUKRAPHAR
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹8 Cr | ₹8 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹-5 Cr | ₹-6 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹3 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹8 Cr | ₹7 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1 Cr | ₹0 Cr | Positive Operating Cash Flow | 6/10 |